Skip to main content
SpringerLink
Log in

Therapeutic Drug Monitoring in Psychiatry

  • Commentary
  • Commentary
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gram LF. Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 1977; 2: 237–51

    Article  PubMed  CAS  Google Scholar 

  2. Schou M, Amdisen A, Baastrup Pc. The practical management of lithium treatment. Br J Hosp Med 1971; 6: 1–8

    Google Scholar 

  3. NIMHlNIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrence. Am J Psychiatry 1985; 142: 496–76

    Google Scholar 

  4. Sashidharan SP. The relationship between serum lithium levels and clinical response. Ther Drug Monit 1982; 4: 249–64

    Article  PubMed  CAS  Google Scholar 

  5. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels oflithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–93

    Article  PubMed  CAS  Google Scholar 

  6. APA Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants — blood level measurements and clinical outcome: an APA Task Force Report. Am J Psychiatry 1985; 142: 155–62

    Google Scholar 

  7. Hansen LB, Larsen N-E. Plasma levels of perphenazine related to clinical effect and extrapyramidal side-effects. In: Gram LF, Usdin E, Dahl SG, et al., editors. Clinical pharmacology in psychiatry. Bridging the experimental-therapeutic gap. London: MacMillan Press Ltd, 1983: 175–81

    Google Scholar 

  8. Kjeldsen CS, Larsen NE, Kragh-Sørensen P, et al. Terapistyring af perfenazinbehandling ved paranoide tilstande. Ugeskr Laeg 1991; 153: 2339–43

    PubMed  CAS  Google Scholar 

  9. Baldessarini RJ, Cohen BM, Teicher MH. Clinical dosing of neuroleptics. In: Gram LF, Balant LP, Meltzer HY, et al., editors. Clinical pharmacology in psychiatry. Strategies in psychotropic drug development. Berlin: Springer-Verlag, 1993: 138–48

    Chapter  Google Scholar 

  10. Gram LF. Fluoxetine (review). New Engl J Med 1994; 331: 1354–61

    Article  PubMed  CAS  Google Scholar 

  11. Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994; 16: 1–12

    Article  PubMed  CAS  Google Scholar 

  12. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism [special article]. Eur J Clin Pharmacol 1989; 36: 537–47

    Article  PubMed  Google Scholar 

  13. Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346: 281–2

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, IMB, Odense University, Winsløwparken 19, DK-5000, Odense, Denmark

    Lars F. Gram

Authors
  1. Lars F. Gram
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gram, L.F. Therapeutic Drug Monitoring in Psychiatry. CNS Drugs 4, 454–455 (1995). https://doi.org/10.2165/00023210-199504060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199504060-00007

Keywords

Search

Navigation